Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 52-week open-label studies

International Clinical Psychopharmacology

Volumn 23, Issue 6, 2008, Pages 343-356

  Emsley, Robin ^a   Berwaerts, Joris ^b   Eerdekens, Mariëlle ^c   Kramer, Michelle ^b   Lane, Rosanne ^b   Lim, Pilar ^b   Hough, David ^b   Palumbo, Joseph ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Long term treatment; Open label extension phase; Paliperidone extended release; Schizophrenia

Indexed keywords

OLANZAPINE; PALIPERIDONE;

ADULT; AGITATION; AKATHISIA; AKINESIA; AMENORRHEA; ANXIETY; ARTICLE; BLEPHAROSPASM; BRADKINESIA; BRADYKINESIA; CHOREA; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLABELLA; GLABELLA REFLEX; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; HYPOKINESIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; MUSCLE SPASM; MUSCLE TWITCH; MUSCULOSKELETAL STIFFNESS; MYOCLONUS; NAUSEA; PAERKINSONISM; PARKINSONISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RATING SCALE; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SINUS TACHYCARDIA; SOMNOLENCE; SUICIDE; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; TRISMUS; WEIGHT CHANGE;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 55849124742     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328314e1f3     Document Type: Article

References (48)

1. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60:1228-1235.
2. Almond S, Knapp M, Francois C, Toumi M, Brugha T (2004). Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184:346-351.
3. American Diabetes Association (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267-272.
4. Ayuso-Gutierrez JL, Ma del Rio Vega J (1997). Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 28:199-206.
5. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
6. Beasley CM Jr, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, et al. (2003). A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 23:582-594.
7. Casey DE (2005). Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 118 (Suppl 2):15S-22S.
8. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD (2006). Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 189:259-266.
9. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group (2002). A comparison of risperidone and haloperidol for the prevention of relapse in schizophrenia. N Engl J Med 346:16-22.
10. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, et al. (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93:117-130.
11. Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, et al. (2005). Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatients Health Outcomes (IC-SOHO) study. J Clin Psychiatry 66:1021-1030.
12. Ereshefsky L, Mascarenas CA (2003). Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 64 (Suppl 16):18-23.
13. Gagnon DD, Nasrallah H, Morosini P-L (2006). Reliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with stable schizophrenia. Int J Neuropsychopharmacol 9 (Suppl 1):S288.
14. GEODON. Prescribing information. Available at: http://wwwpfizercom/ pfizer/ download/uspi_geodonpdf. Accessed 2007.
15. Guy W (1976). ECDEU assessment of manual for psychopharmacology, revised. Rockville, MD: US National Institute of Health, Psychopharmacology Research Branch. pp. 76-338.
16. Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M, et al. (2006). Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 26:571-578.
17. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, et al. (2007). Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17:235-244.
18. Kane J, Canas F, Kramer M, Gassmann C, Lim P, Eerdekens M, et al. (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90:147-161.
19. Kasper S, Brecher M, Fitton L, Jones AM (2004). Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol 19:281-189.
20. Kay S, Opler L, Fizbein A (1986). The positive and negative syndrome scale (PANSS) manual. North Tohawanda, New York: Multi-health System.
21. Keith SJ, Kane JM (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64:1308-1315.
22. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al. (2007). A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 22:433-443.
23. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, et al. (2007). Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 27:6-14.
24. Lambert E, Naber D (2004). Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 18:1-13.
25. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM (2003). Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209-1222.
26. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005a). Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543-1549.
27. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR (2005b). What does the PANSS mean? Schizophr Res 79:231-238.
28. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S (2007). Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 32:1903-1910.
29. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
30. Lublin H, Eberhard J, Levander S (2005). Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 20:183-198.
31. Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538-546.
32. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, et al. (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62:1363-1370.
33. Meltzer H, Kramer M, Gassman-Mayer C, Sherr J, Lim P, Bobo W, et al. (2007). Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled trials. International Congress on Schizophrenia Research. Poster 284.
34. Morosini P-L, Magliano L, Brambilla L, Ugolini S, Pioli R (2000). Development, reliability and acceptability of a new version of the DSM-IV social and occupational social functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101:323-329.
35. Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R (2005). Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv 56:273-282.
36. Nemeroff CB (1997). Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58 (Suppl 10):45-49.
37. Paliperidone extended-release tablets (INVEGA) Prescribing information. Available at: http://wwwjanssencom/active/janus/en_US/assets/common/company/pi/ invegapdf; jsessionid=3HLH4CUHTOA0UCQPCCFTC0YKB2IIQNSC. Accessed June 2007.
38. Patrick D, Morosini P-L, Rothman M (2006). Reliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with acute schizophrenia. Int J Neuropsychopharmacol 9 (Suppl 1):S287-S288.
39. RISPERDAL Prescribing information. Available at: http://wwwfdagov/ cder/foi/ label/2005/020272s042,020588s030,021444s016,021346s010lblpdf. Accessed 2007.
40. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241-247.
41. Rossenu S, Cleton A, Boom S, Alnabawy A, Talluri K, Eerdekens M (2007). Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone with an immediate-release formulation of risperidone. Clin Pharm Ther 81 (Suppl 1):S62.
42. Schooler N, Kane J (1982). Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487.
43. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. (2005). Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 162:938-939.
44. SEROQUEL Prescribing information. Available at: http://wwwastrazeneca- uscom/ pi/seroquelpdf. Accessed 2007.
45. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19.
46. Vermeir M, Boom S, Naessens I, Talluri K, Eerdekens M (2005). Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Eur Neuropsychopharmacol 15 (Suppl 3):S648.
47. Weiden PJ, Olfson M (1995). Cost of relapse in schizophrenia. Schizophr Bull 21:419-429.
48. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D (2007). Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 68:654-661.